Dexmedetomidine Hydrochloride Injection — FDA Drug Shortage

Current — Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)

The FDA lists a drug shortage record for Dexmedetomidine Hydrochloride Injection (injection) from Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) with status Current. The shortage was first posted on Apr 10, 2020. Reported reason: Discontinuation of the manufacture of the drug

Shortage details

Status
Current
Company
Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
Package NDC
83634-600-02
Dosage Form
Injection
Presentation
Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)
Initial Posting
Apr 10, 2020

Reason

Discontinuation of the manufacture of the drug

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.